Advances in Breast Cancer by Med-IQ

Advances in Breast Cancer is organized by Med-IQ and will be held from Oct 11, 2018 - Oct 10, 2019.

Target Audience:
This activity is intended for oncologists and hematologists.

Accreditation/Designation Statements:
Med-IQ designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Conference Description:
This 30-minute webcast reviews recent updates and current clinical evidence in breast cancer management, including the latest surgical techniques, the use of genomic medicine in HR+/HER2- early stage breast cancer, and radiotherapy fractionation for early stage breast cancer.

Statement of Need:
About 12% of women in the United States will develop breast cancer at some point in their lifetimes. The American Cancer Society estimates that approximately 266,120 women will be newly diagnosed with invasive breast cancer and approximately 63,960 women will be newly diagnosed with breast carcinoma in situ in 2018. These women will likely have many questions about their treatment options, including chemotherapy, radiation therapy, and surgery. New clinical findings and evidence, which continue to emerge at a rapid pace, need to be evaluated and applied in clinical practice to best individualize each patient’s care and optimize her outcomes.

Learning Objectives:
Upon completion, participants should be able to:
• Apply genomic medicine to treatment decisions for patients with HR+/HER2- early stage breast cancer
• Assess the range of radiotherapy doses and fractionation schemes that may be appropriate for patients with early stage breast cancer who undergo breast-conserving surgery
• Evaluate select clinical studies on the latest surgical techniques in breast cancer.